We are creating the first commercially available extracorporeal CO2 removal device that uses ultra-low-blood flow to treat patients with hypercarbic respiratory failure. This condition, which causes accumulation of CO2 levels in the blood, can be triggered by many chronic diseases, such as COPD and cystic fibrosis, as well as acute trauma or exposure to toxins. Current medical therapy is inadequate; millions of people around the world suffer from trouble breathing and reduced quality of life. We are changing that with a solution that is:
Instead of pushing the failing lungs to work harder, X-COR directly reconditions blood to allow the lungs to recover.
X-COR Therapeutics is a Boston based medical device company creating the first commercially available CO2 removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure. X-COR was the runner-up in the 2018 Harvard President’s Innovation Challenge with its device, a novel consumable hybrid cartridge that removes CO2 from patients’ blood with less invasive procedures than high-flow alternatives. X-COR is part of the 2018 MedTech Innovator and MassChallenge cohorts.
X-COR’s core technology is a patent-pending medical device that allows physicians to remove excess CO2 from patients who are in symptomatic lung failure and its accompanying control algorithm that is based on machine-learning techniques. The system is compatible with existing medical device infrastructure for ease of use and deployment. Unlike other technologies to treat lung failure, X-COR uses a hybrid approach that allows patients’ blood to be drawn at <300 ml/min flows through small catheters that can be placed by nursing staff. This therapy is more affordable, safer, and more accessible than existing comparable extracorporeal devices that often require >3 L/min flows and highly specialized physicians.
X-COR is led by a team of scientists and engineers with years of experience together.
Jayon Wang, MBA, MS
Jayon received his MBA from Harvard Business School, where he specialized in technology development and new business creation. He was previously the CEO and a co-founder at LifeShel and has worked at big and small firms, ranging from ExxonMobil and Danaher to Lumina Decision Systems.
Brian Y. Chang, PhD
Brian completed his PhD in medical engineering and medical physics within the Harvard-MIT Program in Health Sciences and Technology during which he studied mechanical circulatory support. He previously spent time designing carbon capture systems for power plants at the DOE's NETL.
Steven P. Keller, MD, PhD
Steve is a pulmonary and critical care physician at Brigham and Women’s Hospital where he serves as Medical Director of the ECMO mechanical support service and attends within several intensive care units. He is also affiliated faculty at the Harvard-MIT Biomedical Engineering Center where he conducts research on mechanical circulatory support, organ-device interactions, and extracorporeal organ perfusion.